Results for category "biotechnology company"

Amicus Therapeutics New Jersey – An Intro.

Amicus Therapeutics, a global biotechnology company at the front of all therapies for rare or orphan diseases, has a varied set of platform technologies with medicines in development for those living with rare, devastating diseases, such as the Lysosomal Storage Disorders Fabry disease or the Pompe disease, as well as genetic connective skin disorders like Epidermolysis Bullosa – or EB. The needs of patients within the rare disease community lie at the center of all inventive science, Amicus’s commercial organization, and its diversified clinical programs. Amicus’s goal – stated throughout all levels of each branch – is to make meaningful differences in the lives of all patients and their caregivers.

More information about Amicus and its career opportunities may be found at www.amicusrx.com. Amicus is pleased to submit its new Japanese drug application for its oral precision medicines to combat Fabry disease in Japan. Japan’s a key part of its patient-focused vision in providing migalastat to amenable Fabry patients all over the world – as quickly as possible.

Amicus Therapeutics congratulated Chip Baird for receiving the NJ Tech Council Caren Franzini Hall of Fame Award. Baird’s multiple career achievements have thus elevated him to such recognition among his peers. Team Amicus also spent three days volunteering through Habitat for Humanity’s Monmouth County – HFHMC – division, serving North East and Western Monmouth County within New Jersey. HFHMC sides with communities to develop decent, affordable housing anyone can live and raise a family.

Amicus was also pleased to share positive data from its newest Pompe Phase 1/2 clinical study, which showed a significant step forward in its mission to develop improved treatment options for those living with Pompe disease. Listen to its live conference calls at 8:30am ET to find out more, or access any replay and slide presentations on the website. Amicus likewise shared its first-quarter 2017 financial results and discussed its 2017 key strategic priorities, including an international launching of its precision medicine to combat Fabry disease, advancements of its Pompe disease with Epidermolysis Bullosa clinical programs, and additional corporate updates. The Webcast and replay were available online.

 

Find out more about  Amicus Therapeutics:

https://finance.yahoo.com/quote/FOLD?ltr=1